We use cookies and other tools to enhance your experience on our website and to analyze our web traffic.
For more information about these cookies and the data collected, please refer to our Privacy Policy.

Sleep Heart Health Study

Name Label Folder
nsrrid
NSRR Subject ID
NSRR Subject ID

This subject identifier was created by the National Sleep Research Resource (NSRR) team to more easily match with file downloads. Use 'pptid' to link with Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC) and cohort-specific data.

Administrative
pptidr
Randomized ID: Incorporates parent study random ID
Randomized ID: Incorporates parent study random ID

This participant ID matches what is present in Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC).

Administrative
visitnumber
Sleep Heart Health Study (SHHS) Visit Number
Sleep Heart Health Study (SHHS) Visit Number Administrative
bmi_s1
Body mass index (BMI) (Sleep Heart Health Study Visit One (SHHS1))
Body mass index (BMI) (Sleep Heart Health Study Visit One (SHHS1))

Body Mass Index (BMI) at Sleep Heart Health Study Visit One (SHHS1)

Anthropometry
bmi_s2
Body mass index (BMI) (Sleep Heart Health Study Visit Two (SHHS2))
Body mass index (BMI) (Sleep Heart Health Study Visit Two (SHHS2))

Body Mass Index (BMI) at Sleep Heart Health Study Visit Two (SHHS2)

Anthropometry
height
Height (Sleep Heart Health Study Visit One (SHHS1))
Height (Sleep Heart Health Study Visit One (SHHS1))

The SHHS Coordinating Center bottom and top coded this variable using a lower limit of 145 centimeters and an upper limit of 188 centimeters.

Anthropometry
hip
Hip Circumference (Sleep Heart Health Study Visit One (SHHS1))
Hip Circumference (Sleep Heart Health Study Visit One (SHHS1))

Hip measurement in centimeters

Anthropometry
pm202
Weight (Sleep Heart Health Study Visit Two (SHHS2))
Weight (Sleep Heart Health Study Visit Two (SHHS2))

The SHHS Coordinating Center bottom and top coded this variable using a lower limit of 47 kilograms and an upper limit of 126 kilograms.

Anthropometry
pm207
Height (Sleep Heart Health Study Visit Two (SHHS2))
Height (Sleep Heart Health Study Visit Two (SHHS2))

The SHHS Coordinating Center bottom and top coded this variable using a lower limit of 145 centimeters and an upper limit of 188 centimeters.

Anthropometry
waist
Waist Circumference (Sleep Heart Health Study Visit One (SHHS1))
Waist Circumference (Sleep Heart Health Study Visit One (SHHS1))

Waist measurement in centimeters

Anthropometry
weight
Weight (Sleep Heart Health Study Visit One (SHHS1))
Weight (Sleep Heart Health Study Visit One (SHHS1))

The SHHS Coordinating Center bottom and top coded this variable using a lower limit of 47 kilograms and an upper limit of 126 kilograms.

Anthropometry
fev1
Forced Expiratory Volume (FEV 1) (Sleep Heart Health Study Visit One (SHHS1))
Forced Expiratory Volume (FEV 1) (Sleep Heart Health Study Visit One (SHHS1))

in One Second

Clinical Data/Diagnostic Studies/Lung Function
fvc
Forced Vital Capacity (FVC) (Sleep Heart Health Study Visit One (SHHS1))
Forced Vital Capacity (FVC) (Sleep Heart Health Study Visit One (SHHS1)) Clinical Data/Diagnostic Studies/Lung Function
afibincident
Incident Atrial Fibrillation (AF) after SHHS Visit 1
Incident Atrial Fibrillation (AF) after SHHS Visit 1

Variable created as part of the analysis for Tung et al. 2017 (PubMed ID: 28668820). Incident AF was considered present if AF was identified on a 12-lead ECG obtained at the second SHHS exam or was adjudicated by the parent cohorts at any time between the baseline PSG and the final follow-up date for AF ascertainment of June 30, 2006.

Clinical Data/Incident Outcomes/Cardiovascular Diseases
afibprevalent
Prevalent Atrial Fibrillation (AF) at SHHS Visit 1
Prevalent Atrial Fibrillation (AF) at SHHS Visit 1

Variable created as part of the analysis for Tung et al. 2017 (PubMed ID: 28668820). Prevalent AF was defined by any of the following: a positive response to the question 'Has a doctor ever told you that you have or had atrial fibrillation'; AF identified on resting 12-lead ECG at the baseline SHHS exam; or if the parent study identified AF documented in the medical record before the SHHS baseline exam.

Clinical Data/Incident Outcomes/Cardiovascular Diseases
angina
Number of Angina Episodes Since Baseline
Number of Angina Episodes Since Baseline

Angina episodes since baseline Polysomnogram (PSG) (as recorded in parent studies datasets)

Clinical Data/Incident Outcomes/Cardiovascular Diseases
any_chd
Any Coronary Heart Disease (CHD) Since Baseline?
Any Coronary Heart Disease (CHD) Since Baseline?

Any Coronary Heart Disease (CHD) since baseline Polysomnogram (PSG) (as recorded in parent studies datasets)

Clinical Data/Incident Outcomes/Cardiovascular Diseases
any_cvd
Any Cardiovascular Disease (CVD) Since Baseline?
Any Cardiovascular Disease (CVD) Since Baseline?

Any Cardiovascular Disease (CVD) since baseline Polysomnogram (PSG) (as recorded in parent studies datasets)

Clinical Data/Incident Outcomes/Cardiovascular Diseases
cabg
Number of coronary artery bypass graft surgeries (CABGs) Since Baseline
Number of coronary artery bypass graft surgeries (CABGs) Since Baseline

coronary artery bypass graft surgery (CABG) since baseline Polysomnogram (PSG) (as recorded in parent studies datasets)

Clinical Data/Incident Outcomes/Cardiovascular Diseases
chd_death
Fatal Coronary Heart Disease (CHD) Since Baseline?
Fatal Coronary Heart Disease (CHD) Since Baseline?

Coronary Heart Disease (CHD) death (as recorded in parent studies datasets)

Clinical Data/Incident Outcomes/Cardiovascular Diseases
chf
Number of Congestive Heart Failures (CHFs) Since to Baseline
Number of Congestive Heart Failures (CHFs) Since to Baseline

Congestive Heart Failure (CHF) since baseline Polysomnogram (PSG) (as recorded in parent studies datasets)

Clinical Data/Incident Outcomes/Cardiovascular Diseases
cvd_death
Fatal Cardiovascular Disease (CVD) Since Baseline?
Fatal Cardiovascular Disease (CVD) Since Baseline?

Cardiovascular Disease (CVD) death (as recorded in parent studies datasets)

Clinical Data/Incident Outcomes/Cardiovascular Diseases
mi
Number of myocardial infarctions (MIs) Since Baseline
Number of myocardial infarctions (MIs) Since Baseline

Myocardial infarction (MI) since baseline Polysomnogram (PSG) (as recorded in parent studies datasets)

Clinical Data/Incident Outcomes/Cardiovascular Diseases
mi_death
Death from myocardial infarct (MI) since Baseline?
Death from myocardial infarct (MI) since Baseline? Clinical Data/Incident Outcomes/Cardiovascular Diseases
mi_fatal
Fatal Heart Attack Since Baseline?
Fatal Heart Attack Since Baseline?

Fatal myocardial infarction (MI) since baseline Polysomnogram (PSG) (as recorded in parent studies datasets)

Clinical Data/Incident Outcomes/Cardiovascular Diseases
mip
Number of Procedures Related to Heart Attack Since Baseline
Number of Procedures Related to Heart Attack Since Baseline

Myocardial infarction (MI) procedure since baseline Polysomnogram (PSG) (as recorded in parent studies datasets)

Clinical Data/Incident Outcomes/Cardiovascular Diseases
prev_ang
Number of Angina Episodes Prior to Baseline
Number of Angina Episodes Prior to Baseline

Angina episodes prior to baseline Polysomnography (PSG) (as recorded in parent studies datasets)

Clinical Data/Incident Outcomes/Cardiovascular Diseases
prev_chf
Number of Congestive Heart Failure (CHF) episodes Prior to Baseline
Number of Congestive Heart Failure (CHF) episodes Prior to Baseline

Congestive Heart Failure (CHF) episodes prior to baseline Polysomnography (PSG) (as recorded in parent studies datasets)

Clinical Data/Incident Outcomes/Cardiovascular Diseases
prev_mi
Number of myocardial infarctions (MIs) Prior to Baseline
Number of myocardial infarctions (MIs) Prior to Baseline

Myocardial infarction (MI) prior to baseline Polysomnography (PSG) (as recorded in parent studies datasets)

Clinical Data/Incident Outcomes/Cardiovascular Diseases
prev_mip
Number of Procedures Related to Heart Attack Prior to Baseline
Number of Procedures Related to Heart Attack Prior to Baseline

Myocardial infarction (MI)/procedure prior to baseline Polysomnography (PSG) (as recorded in parent studies datasets)

Clinical Data/Incident Outcomes/Cardiovascular Diseases
prev_revpro
Number of Revascularization Procedures Prior to Baseline
Number of Revascularization Procedures Prior to Baseline

Revascularization procedure prior to baseline Polysomnography (PSG) (as recorded in parent studies datasets)

Clinical Data/Incident Outcomes/Cardiovascular Diseases
prev_stk
Number of Strokes Prior to Baseline
Number of Strokes Prior to Baseline

Stroke prior to baseline Polysomnography (PSG) (as recorded in parent studies datasets)

Clinical Data/Incident Outcomes/Cardiovascular Diseases
ptca
Number of Percutaneous transluminal coronary angioplasties (PTCAs) Since Baseline
Number of Percutaneous transluminal coronary angioplasties (PTCAs) Since Baseline

Percutaneous transluminal coronary angioplasty (PTCA) since baseline Polysomnogram (PSG) (as recorded in parent studies datasets)

Clinical Data/Incident Outcomes/Cardiovascular Diseases
revasc_proc
Number of Revascularization Procedures Since Baseline
Number of Revascularization Procedures Since Baseline

Revascularization procedure since baseline Polysomnogram (PSG) (as recorded in parent studies datasets)

Clinical Data/Incident Outcomes/Cardiovascular Diseases
stk_fatal
Fatal Stroke Since Baseline?
Fatal Stroke Since Baseline?

Fatal stroke since baseline Polysomnogram (PSG) (as recorded in parent studies datasets)

Clinical Data/Incident Outcomes/Cardiovascular Diseases
stroke
Number of Strokes Since Baseline
Number of Strokes Since Baseline

Stroke since baseline Polysomnogram (PSG) (as recorded in parent studies datasets)

Clinical Data/Incident Outcomes/Cardiovascular Diseases
vital
Vital status at last contact
Vital status at last contact

Deaths from any cause were identified and confirmed for the cohort using multiple concurrent approaches including follow-up interviews, written annual questionnaires or telephone contacts with study participants or next-of-kin, surveillance of local hospital records and community obituaries, and linkage with the Social Security Administration Death Master File. (For more information, see Punjabi et al. 2009 (PubMed ID: 19688045))

Clinical Data/Incident Outcomes/Cardiovascular Diseases
chol
Cholesterol
Cholesterol Clinical Data/Laboratory Tests
hdl
High-density lipoprotein (HDL) cholesterol
High-density lipoprotein (HDL) cholesterol Clinical Data/Laboratory Tests
trig
Triglycerides
Triglycerides Clinical Data/Laboratory Tests
diasbp
Average Diastolic blood pressure (BP) (Sleep Heart Health Study Visit One (SHHS1))
Average Diastolic blood pressure (BP) (Sleep Heart Health Study Visit One (SHHS1))

Seated Diastolic Blood Pressure (BP)

Clinical Data/Vital Signs/Seated Blood Pressure/SHHS1
systbp
Average Systolic blood pressure (BP) (Sleep Heart Health Study Visit One (SHHS1))
Average Systolic blood pressure (BP) (Sleep Heart Health Study Visit One (SHHS1))

Seated Systolic Blood Pressure (BP) (Average of two measurements)

Clinical Data/Vital Signs/Seated Blood Pressure/SHHS1
avg23bpd_s2
Average Diastolic blood pressure (BP) (Sleep Heart Health Study Visit Two (SHHS2))
Average Diastolic blood pressure (BP) (Sleep Heart Health Study Visit Two (SHHS2))

Average of 2nd and 3rd Diastolic Blood Pressure (BP) measures

Clinical Data/Vital Signs/Seated Blood Pressure/SHHS2
avg23bps_s2
Average Systolic blood pressure (BP) (Sleep Heart Health Study Visit Two (SHHS2))
Average Systolic blood pressure (BP) (Sleep Heart Health Study Visit Two (SHHS2))

Average of 2nd and 3rd Systolic Blood Pressure (BP) measures

Clinical Data/Vital Signs/Seated Blood Pressure/SHHS2
ethnicity
Ethnicity (Hispanic or Latino) of the participant
Ethnicity (Hispanic or Latino) of the participant

Note: This variable was derived from race and was not asked as a separate demographic question. At the time of SHHS Visit 1, race and ethnicity were collected together in a single question. This variable was derived later on when the datasets were prepared for deposition in Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC).

Demographics
gender
Gender of the participant
Gender of the participant

Gender as reported by Parent Cohort

Demographics
race
Race of the participant
Race of the participant

Race is presented as three (3) categories based on suggested Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC) de-identification procedures.

Demographics
educat
Education level of the participant
Education level of the participant Demographics/Education
age_category_s1
Age at Sleep Heart Health Study Visit One (SHHS1)
Age at Sleep Heart Health Study Visit One (SHHS1)

Age at time of study in years, based on start date of Sleep Heart Health Study Visit One (SHHS1) Polysomnography (PSG) recording.

Demographics/SHHS1
age_s1
Age at Sleep Heart Health Study Visit One (SHHS1)
Age at Sleep Heart Health Study Visit One (SHHS1)

Age at time of study in years, based on start date of Sleep Heart Health Study Visit One (SHHS1) Polysomnography (PSG) recording. Values equal to 90 indicate an age of 90 or greater.

Demographics/SHHS1
mstat
Marital status of the participant
Marital status of the participant Demographics/SHHS1
age_category_s2
Age at Sleep Heart Health Study Visit Two (SHHS2)
Age at Sleep Heart Health Study Visit Two (SHHS2)

Age at time of study in years, based on start date of Sleep Heart Health Study Visit One (SHHS1) Polysomnography (PSG) recording.

Demographics/SHHS2
age_s2
Age at Sleep Heart Health Study Visit Two (SHHS2)
Age at Sleep Heart Health Study Visit Two (SHHS2)

Age in years at the time of the Sleep Heart Health Study Visit Two (SHHS2) visit. Values equal to 90 indicate an age of 90 or greater.

Demographics/SHHS2
nsrr_bmi
Body mass index (BMI)
Body mass index (BMI)

Harmonized by the NSRR team to align with TOPMed and BioDataCatalyst standards. Source: bmi_s1 at Visit 1, and bmi_s2 at Visit 2

Harmonized/Anthropometry
nsrr_bp_diastolic
Diastolic blood pressure
Diastolic blood pressure

Average resting diastolic blood pressure of two measurements collected from the upper arm in a single clinic visit. When more than two measurements were collected, the average was calculated using the second and third measurements. In cases where either of the measurements was missing, the average was calculated discarding the missing value.

Harmonized by the NSRR team to align with TOPMed and BioDataCatalyst standards. Source: diasbp

Harmonized/Clinical Data
nsrr_bp_systolic
Systolic blood pressure
Systolic blood pressure

Average resting systolic blood pressure of two measurements collected from the upper arm in a single clinic visit. When more than two measurements were collected, the average was calculated using the second and third measurements. In cases where either of the measurements was missing, the average was calculated discarding the missing value.

Harmonized by the NSRR team to align with TOPMed and BioDataCatalyst standards. Source: systbp

Harmonized/Clinical Data
nsrr_age
Subject age
Subject age

Harmonized by the NSRR team to align with TOPMed and BioDataCatalyst standards. Source: age_s1 at Visit 1 and age_s2 at Visit 2

Harmonized/Demographics
nsrr_age_gt89
Indicates whether the subject's age (in years) used during date obfuscation is greater than 89 years
Indicates whether the subject's age (in years) used during date obfuscation is greater than 89 years

Harmonized by the NSRR team to align with TOPMed and BioDataCatalyst standards. Source: age_s1 at Visit 1 and age_s2 at Visit 2

Harmonized/Demographics
nsrr_ethnicity
Subject ethnicity
Subject ethnicity

Original missing value is recoded as "not reported".

Harmonized by the NSRR team to align with TOPMed and BioDataCatalyst standards. Source: ethnicity

Harmonized/Demographics
nsrr_race
Subject race
Subject race

Harmonized by the NSRR team to align with TOPMed and BioDataCatalyst standards. Source: race

Harmonized/Demographics
nsrr_sex
Subject sex
Subject sex

Harmonized by the NSRR team to align with TOPMed and BioDataCatalyst standards. Source: gender

Harmonized/Demographics
nsrr_current_smoker
Currently smoking cigarettes
Currently smoking cigarettes

Indicates whether subject currently smokes cigarettes.

Harmonized by the NSRR team to align with TOPMed and BioDataCatalyst standards. Source: smokstat_s1 at Visit 1 and smokstat_s2 at Visit 2

Harmonized/Lifestyle and Behavioral Health
nsrr_ever_smoker
Ever smoked cigarettes
Ever smoked cigarettes

Indicates whether subject ever regularly smoked cigarettes.

Harmonized by the NSRR team to align with TOPMed and BioDataCatalyst standards. Source: smokstat_s1 at Visit 1 and smokstat_s2 at Visit 2

Harmonized/Lifestyle and Behavioral Health
nsrr_ahi_hp3r_aasm15
Apnea-Hypopnea Index : (All apneas + hypopneas with >=30% nasal cannula [or alternative sensor] reduction and >= 3% oxygen desaturation or with arousal) / hour of sleep
Apnea-Hypopnea Index : (All apneas + hypopneas with >=30% nasal cannula [or alternative sensor] reduction and >= 3% oxygen desaturation or with arousal) / hour of sleep

Harmonized by the NSRR team.

The definition for hypopneas is consistent with the following clinical guidelines: (1) American Academy of Sleep Medicine (AASM) 2007 Manual (2012 update) (recommended). Berry RB et al. 2012 (PubMed ID:23066376), and (2) American Academy of Sleep Medicine (AASM) 2015 (recommended) [Berry RB et al. The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications, Version 2.2. American Academy of Sleep Medicine, Darien, IL, 2015.]

Refer to the source for detailed definition for respiratory events: ahi_a0h3a

Harmonized/Polysomnography/Apnea-Hypopnea Indices
nsrr_ahi_hp3u
Apnea-Hypopnea Index : (All apneas + hypopneas with >= 3% oxygen desaturation) / hour of sleep
Apnea-Hypopnea Index : (All apneas + hypopneas with >= 3% oxygen desaturation) / hour of sleep

Harmonized by the NSRR team. Refer to the source for detailed definition for respiratory events: ahi_a0h3

Harmonized/Polysomnography/Apnea-Hypopnea Indices
nsrr_ahi_hp4r
Apnea-Hypopnea Index : (All apneas + hypopneas with >= 4% oxygen desaturation or with arousal) / hour of sleep
Apnea-Hypopnea Index : (All apneas + hypopneas with >= 4% oxygen desaturation or with arousal) / hour of sleep

Harmonized by the NSRR team. Refer to the source for detailed definition for respiratory events: ahi_a0h4a

Harmonized/Polysomnography/Apnea-Hypopnea Indices
nsrr_ahi_hp4u_aasm15
Apnea-Hypopnea Index : (All apneas + hypopneas with >=30% nasal cannula [or alternative sensor] reduction with >= 4% oxygen desaturation) / hour of sleep
Apnea-Hypopnea Index : (All apneas + hypopneas with >=30% nasal cannula [or alternative sensor] reduction with >= 4% oxygen desaturation) / hour of sleep

Harmonized by the NSRR team.

The definition of hypopnea events is consistent with the following clinical guidelines: (1) AASM 2012 update (alternative) Berry RB et al. 2012 (PubMed ID:23066376), and (2) AASM 2015 (acceptable) [Berry RB et al. The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications, Version 2.2. American Academy of Sleep Medicine, Darien, IL, 2015.].

Refer to the source for detailed definition for respiratory events: ahi_a0h4

Harmonized/Polysomnography/Apnea-Hypopnea Indices
nsrr_phrnumar_f1
Arousal Index: Number of arousals per hour of sleep from polysomnography
Arousal Index: Number of arousals per hour of sleep from polysomnography

Harmonized by the NSRR team. Source: ai_all

Harmonized/Polysomnography/Arousal
nsrr_pctdursp_s1
Percentage of total sleep duration (i.e., total sleep time, TST) in stage 1 from polysomnography
Percentage of total sleep duration (i.e., total sleep time, TST) in stage 1 from polysomnography

Harmonized by the NSRR team. Source: timest1p

Harmonized/Polysomnography/Sleep Architecture
nsrr_pctdursp_s2
Percentage of total sleep duration (i.e., total sleep time, TST) in stage 2 from polysomnography
Percentage of total sleep duration (i.e., total sleep time, TST) in stage 2 from polysomnography

Harmonized by the NSRR team. Source: timest2p

Harmonized/Polysomnography/Sleep Architecture
nsrr_pctdursp_s3
Percentage of total sleep duration (i.e., total sleep time, TST) in stage 3/4 from polysomnography
Percentage of total sleep duration (i.e., total sleep time, TST) in stage 3/4 from polysomnography

Harmonized by the NSRR team. Source: times34p

Harmonized/Polysomnography/Sleep Architecture
nsrr_pctdursp_sr
Percentage of total sleep duration (i.e., total sleep time, TST) in REM from polysomnography
Percentage of total sleep duration (i.e., total sleep time, TST) in REM from polysomnography

Harmonized by the NSRR team. Source: timeremp

Harmonized/Polysomnography/Sleep Architecture
nsrr_ttldursp_f1
Total Sleep Duration: the interval between sleep onset and sleep offset while the participant is asleep from polysomnography
Total Sleep Duration: the interval between sleep onset and sleep offset while the participant is asleep from polysomnography

Conventionally, this would be called total sleep time (TST) (i.e. total time spent in stage 1 or greater).

Harmonized by the NSRR team. Source: slpprdp

Harmonized/Polysomnography/Sleep Architecture
nsrr_ttldursp_s1sr
REM Sleep Latency: the interval between the first sleep epoch and REM sleep excluding wake
REM Sleep Latency: the interval between the first sleep epoch and REM sleep excluding wake

Harmonized by the NSRR team. Source: remlaiip

Harmonized/Polysomnography/Sleep Architecture
nsrr_ttldurws_f1
Wake After Sleep Onset: the total duration being awake between sleep onset and lights-on/out-bed time from polysomnography
Wake After Sleep Onset: the total duration being awake between sleep onset and lights-on/out-bed time from polysomnography

Harmonized by the NSRR team. Source: waso

Harmonized/Polysomnography/Sleep Architecture
nsrr_ttleffsp_f1
Sleep Efficiency: the ratio of total sleep duration (i.e., total sleep time) to in-bed period (i.e., time in bed) from polysomnography
Sleep Efficiency: the ratio of total sleep duration (i.e., total sleep time) to in-bed period (i.e., time in bed) from polysomnography

Harmonized by the NSRR team. Source: slpeffp

Harmonized/Polysomnography/Sleep Architecture
nsrr_ttllatsp_f1
Sleep Latency: the interval between lights-out/in-bed time and sleep onset from polysomnography
Sleep Latency: the interval between lights-out/in-bed time and sleep onset from polysomnography

Harmonized by the NSRR team. Source: slplatp

Harmonized/Polysomnography/Sleep Architecture
nsrr_ttlprdbd_f1
Total In-bed Period: the interval between lights off/in-bed time and lights on/out-bed time from polysomnography
Total In-bed Period: the interval between lights off/in-bed time and lights on/out-bed time from polysomnography

Harmonized by the NSRR team. Conventionally, this would be called time in bed (TIB)

Source: timebedp

Harmonized/Polysomnography/Sleep Architecture
nsrr_ttlprdsp_s1sr
REM Sleep Latency: the interval between the first sleep epoch and REM sleep including wake
REM Sleep Latency: the interval between the first sleep epoch and REM sleep including wake

Harmonized by the NSRR team. Source: remlaip

Harmonized/Polysomnography/Sleep Architecture
smokstat_s1
Smoking Status at Sleep Heart Health Study Visit One (SHHS1)
Smoking Status at Sleep Heart Health Study Visit One (SHHS1)

Current Smoking Status at the Sleep Heart Health Study Visit One (SHHS1) visit

Lifestyle and Behavioral Health/SHHS1
smokstat_s2
Smoking Status at Sleep Heart Health Study Visit Two (SHHS2)
Smoking Status at Sleep Heart Health Study Visit Two (SHHS2)

Current Smoking Status at the Sleep Heart Health Study Visit Two (SHHS2)

Lifestyle and Behavioral Health/SHHS2
ace1
angiotensin-converting-enzyme inhibitor (ACE) inhibitors without diuretics (Sleep Heart Health Study Visit One (SHHS1))
angiotensin-converting-enzyme inhibitor (ACE) inhibitors without diuretics (Sleep Heart Health Study Visit One (SHHS1))

Participant taking angiotensin-converting-enzyme inhibitor (ACE) INHIBITORS WITHOUT DIURETICS within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Medical History/Medications/SHHS1
aced1
angiotensin-converting-enzyme inhibitor (ACE) inhibitors with diuretics (Sleep Heart Health Study Visit One (SHHS1))
angiotensin-converting-enzyme inhibitor (ACE) inhibitors with diuretics (Sleep Heart Health Study Visit One (SHHS1))

Participant taking angiotensin-converting-enzyme inhibitor (ACE) INHIBITORS WITH DIURETICS within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Medical History/Medications/SHHS1
anar1a1
Anti-Arrhythmics, Class 1A (Sleep Heart Health Study Visit One (SHHS1))
Anti-Arrhythmics, Class 1A (Sleep Heart Health Study Visit One (SHHS1))

Participant taking ANTI-ARRHYTHMICS, CLASS 1A within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Medical History/Medications/SHHS1
anar1b1
Anti-Arrhythmics, Class 1B (Sleep Heart Health Study Visit One (SHHS1))
Anti-Arrhythmics, Class 1B (Sleep Heart Health Study Visit One (SHHS1))

Participant taking ANTI-ARRHYTHMICS, CLASS 1B within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Medical History/Medications/SHHS1
anar1c1
Anti-Arrhythmics, Class 1C (Sleep Heart Health Study Visit One (SHHS1))
Anti-Arrhythmics, Class 1C (Sleep Heart Health Study Visit One (SHHS1))

Participant taking ANTI-ARRHYTHMICS, CLASS 1C within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Medical History/Medications/SHHS1
anar31
Anti-Arrhythmics, Class 3 (Sleep Heart Health Study Visit One (SHHS1))
Anti-Arrhythmics, Class 3 (Sleep Heart Health Study Visit One (SHHS1))

Participant taking ANTI-ARRHYTHMICS, CLASS 3 within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Medical History/Medications/SHHS1
benzod1
Benzodiazepines (Sleep Heart Health Study Visit One (SHHS1))
Benzodiazepines (Sleep Heart Health Study Visit One (SHHS1))

Participant taking BENZODIAZEPINES within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Medical History/Medications/SHHS1
beta1
Beta-blockers without diuretics (Sleep Heart Health Study Visit One (SHHS1))
Beta-blockers without diuretics (Sleep Heart Health Study Visit One (SHHS1))

Participant taking BETA-BLOCKERS WITHOUT DIURETICS within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Medical History/Medications/SHHS1
betad1
Beta-blockers with diuretics (Sleep Heart Health Study Visit One (SHHS1))
Beta-blockers with diuretics (Sleep Heart Health Study Visit One (SHHS1))

Participant taking BETA-BLOCKERS WITH DIURETICS within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Medical History/Medications/SHHS1
ccb1
Any calcium-channel blocker = CCIR or CCBSR or CCBT (Sleep Heart Health Study Visit One (SHHS1))
Any calcium-channel blocker = CCIR or CCBSR or CCBT (Sleep Heart Health Study Visit One (SHHS1))

Participant taking ANY CALCIUM-CHANNEL BLOCKER = CCIR OR CCBSR OR CCBT within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Medical History/Medications/SHHS1
diuret1
Any diuretic (Sleep Heart Health Study Visit One (SHHS1))
Any diuretic (Sleep Heart Health Study Visit One (SHHS1))

Participant taking ANY DIURETIC within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Medical History/Medications/SHHS1
htnmed1
Any Anti-Hypertensive Medication (Sleep Heart Health Study Visit One (SHHS1))
Any Anti-Hypertensive Medication (Sleep Heart Health Study Visit One (SHHS1))

Participant taking ANY ANTI-HYPERTENSIVE MEDICATION within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Medical History/Medications/SHHS1
insuln1
Insulins (Sleep Heart Health Study Visit One (SHHS1))
Insulins (Sleep Heart Health Study Visit One (SHHS1))

Participant taking INSULINS within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Medical History/Medications/SHHS1
istrd1
Inhaled steroids for asthma (Sleep Heart Health Study Visit One (SHHS1))
Inhaled steroids for asthma (Sleep Heart Health Study Visit One (SHHS1))

Participant taking INHALED STEROIDS FOR ASTHMA within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Medical History/Medications/SHHS1
lipid1
Any Lipid-Lowering Medication (Sleep Heart Health Study Visit One (SHHS1))
Any Lipid-Lowering Medication (Sleep Heart Health Study Visit One (SHHS1))

Participant taking ANY LIPID-LOWERING MEDICATION within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Medical History/Medications/SHHS1
nsaid1
Non-Steroidal Anti-Inflammatory Agents, Excluding Aspirin (Sleep Heart Health Study Visit One (SHHS1))
Non-Steroidal Anti-Inflammatory Agents, Excluding Aspirin (Sleep Heart Health Study Visit One (SHHS1))

Participant taking NON-STEROIDAL ANTI-INFLAMMATORY AGENTS, EXCLUDING ASPIRIN within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Medical History/Medications/SHHS1
ntca1
Non-Tricyclic Antidepressants Other Than monoamine oxidase inhibitor (MAOI) (Sleep Heart Health Study Visit One (SHHS1))
Non-Tricyclic Antidepressants Other Than monoamine oxidase inhibitor (MAOI) (Sleep Heart Health Study Visit One (SHHS1))

Participant taking NON-TRICYCLIC ANTIDEPRESSANTS OTHER THAN monoamine oxidase inhibitor (MAOI) within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Medical History/Medications/SHHS1
ntg1
Nitrates (Sleep Heart Health Study Visit One (SHHS1))
Nitrates (Sleep Heart Health Study Visit One (SHHS1))

Participant taking NITRATES within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Medical History/Medications/SHHS1
ohga1
Oral Hypoglycemic Agents (Sleep Heart Health Study Visit One (SHHS1))
Oral Hypoglycemic Agents (Sleep Heart Health Study Visit One (SHHS1))

Participant taking ORAL HYPOGLYCEMIC AGENTS within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Medical History/Medications/SHHS1